SynthesisAnnals of family medicine
Metformin as treatment for overweight and obese adults: a systematic review.
Synthesis in Annals of family medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2019Pooled it
- Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.The Cochrane database of systematic reviews · 2018Pooled it
- Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.Journal of clinical pharmacology · 2017Trial
- Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain.PloS one · 2014 · on this mapTrial
- Obesity and Women's health across the lifespan: A clinical review of life Stage-Specific challenges and treatment considerations.Obesity pillars · 2026Review
- The Regulatory Effects of Exercise and Metformin on Biomarkers in Obesity: A Focus on Uric Acid, Irisin, Adiponutrin, Adropin, and Copeptin.Medicina (Kaunas, Lithuania) · 2025Article
- Impact of immediate-release versus extended-release metformin on lipid profile and body measurements in Saudi patients with type 2 diabetes: a prospective cohort study.The Pan African medical journal · 2025Article
- Article
- Review
- Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target.International journal of molecular sciences · 2023Article
- The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems.Scientific reports · 2021Article
- Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Identification of drug combinations on the basis of machine learning to maximize anti-aging effects.PloS one · 2021Article
- Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity.Nutrients · 2020Article
- Metformin: Mechanisms in Human Obesity and Weight Loss.Current obesity reports · 2019Review
- Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.BMJ open · 2019 · on this mapArticle
- The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure.Behavioural neurology · 2019Review
- Microbiota and metabolic diseases.Endocrine · 2018Review
- Metformin Use and Severe Dengue in Diabetic Adults.Scientific reports · 2018 · on this mapArticle
- Differential sympathetic outflow to adipose depots is required for visceral fat loss in response to calorie restriction.Nutrition & diabetes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe wanted to determine whether metformin is an effective medication for treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome (PCOS).
methodsWe searched MEDLINE (1966-2003), EMBASE (1986-2003), Allied and Complementary Medicine Database (1985-2003), International Pharmaceutical Abstracts (1970-2003), the Cochrane Library, American College of Physicians Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Controlled Trials Register, MEDLINE In-Process & Other Non-Indexed Citations, reference lists of retrieved articles, and articles by selected authors and pharmaceutical manufacturers. Inclusion criteria were being obese or overweight determined by a BMI of 25 kg/m2 or greater or waist-to-hip ratio (WHR) of more than 0.8, metformin use, and aged 18 years or older. Exclusion criteria were a diagnosis of diabetes mellitus, polycystic ovarian syndrome or descriptors of polycystic ovarian syndrome, human immunodeficiency virus infection, and concomitant antipsychotic medications. Trials were graded on an 11-point Jadad scale. Only randomized controlled and blinded trials were accepted. Two reviewers independently extracted data from each trial. Primary outcomes measured were changes in BMI, WHR, and weight.
resultsFifty-seven potentially relevant studies were initially identified; 48 were excluded because of lack of randomization, lack of blinding, failure to meet inclusion or exclusion criteria, inaccessible outcomes, or improper study design. Nine clinical trials met criteria for validity assessment. Four studies used the parameter of waist-to-hip ratio, 3 studies included BMI, and 8 used weight. Two of the 9 studies showed a small reduction in WHR.
conclusionInsufficient evidence exists for the use of metformin as treatment of overweight or obese adults who do not have diabetes mellitus or polycystic ovary syndrome. Further studies are needed to answer this clinical question.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.